{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:49:51Z","timestamp":1782953391500,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AZV","award":["NU23-01-00288"],"award-info":[{"award-number":["NU23-01-00288"]}]},{"name":"Czech Ministry of Health","award":["RVO-VFN64165"],"award-info":[{"award-number":["RVO-VFN64165"]}]},{"name":"New Technologies for Translational Research in Pharmaceutical Sciences \/NETPHARM project","award":["CZ.02.01.01\/00\/22_008\/0004607"],"award-info":[{"award-number":["CZ.02.01.01\/00\/22_008\/0004607"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Portal hypertension (PH) is one of the major complications of liver cirrhosis, traditionally assessed using invasive methods such as the hepatic venous pressure gradient (HVPG). Soluble endoglin (sENG), a marker of endothelial dysfunction and fibrosis, has been proposed as a non-invasive biomarker of various liver diseases. This study aimed to evaluate serum sENG concentrations in cirrhotic patients with PH and investigate its relationship with PH severity, alcohol consumption, and smoking. Serum concentrations of sENG were measured in clinically well-examined patients with liver cirrhosis (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200960, age range 24\u201382 years) with PH classified as mild, moderate, or severe according to the HVPG values measured invasively using the classical wedge technique. sENG concentrations were also compared to healthy controls (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200954). Liver enzyme activities, alcohol consumption history, and smoking habits were also recorded to assess their association with sENG. sENG concentrations were significantly higher in patients with PH compared to healthy controls (6.31; 5.14\u20137.30 vs. 3.70; 3.24\u20134.20 ng\/mL,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) but did not correlate with the severity of HVPG-diagnosed portal hypertension. A moderately significant correlation was observed between sENG concentrations and GGT activities (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Alcohol consumption, but not smoking, was associated with higher serum sENG concentrations (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01). Based on our results, sENG appears to be a non-invasive marker of endothelial dysfunction\/fibrosis in cirrhotic patients with PH, particularly in alcohol-related liver disease. Although it does not reflect PH severity and thus cannot be used as a diagnostic tool, it has the potential for early disease detection and risk prediction as a screening component in non-invasive approaches in clinical hepatology.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-51523-w","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:58:11Z","timestamp":1777705091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Soluble endoglin as a marker of clinically significant portal hypertension in patients with cirrhosis"],"prefix":"10.1038","volume":"16","author":[{"given":"Ivone Cristina","family":"Igreja Sa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaclav","family":"Smid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Fikrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana Urbankov\u00e1","family":"Rathouska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Nemeckova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Tripska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Diepoltova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SeyedehNiloufar","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ctirad","family":"Andrys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaromir","family":"Petrtyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radan","family":"Bruha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libor","family":"Vitek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Nachtigal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"51523_CR1","doi-asserted-by":"publisher","first-page":"e70127","DOI":"10.1111\/liv.70127","volume":"45","author":"JM Paik","year":"2025","unstructured":"Paik, J. M., Henry, L. & Younossi, Z. M. The Global Burden of MASLD in the Past Three Decades. Liver Int. 45, e70127 (2025).","journal-title":"Liver Int."},{"key":"51523_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi, H. et al. Global burden of liver disease: 2023 update. J. Hepatol. 79, 516\u2013537 (2023).","journal-title":"J. Hepatol."},{"key":"51523_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41392-024-02072-z","volume":"10","author":"C Gan","year":"2025","unstructured":"Gan, C. et al. Liver diseases: epidemiology, causes, trends and predictions. Signal. Transduct. Target. Ther. 10, 33 (2025).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"51523_CR4","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jhep.2018.05.011","volume":"69","author":"L Pimpin","year":"2018","unstructured":"Pimpin, L. et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. J. Hepatol. 69, 718\u2013735 (2018).","journal-title":"J. Hepatol."},{"key":"51523_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/hep.20062","volume":"39","author":"RJ Groszmann","year":"2004","unstructured":"Groszmann, R. J. & Wongcharatrawee, S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 39, 280\u2013282 (2004).","journal-title":"Hepatology"},{"key":"51523_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.2174\/15665240113139990058","volume":"13","author":"B Oujo","year":"2013","unstructured":"Oujo, B., Perez-Barriocanal, F., Bernabeu, C. & Lopez-Novoa, J. M. Membrane and soluble forms of endoglin in preeclampsia. Curr. Mol. Med. 13, 1345\u20131357 (2013).","journal-title":"Curr. Mol. Med."},{"key":"51523_CR7","doi-asserted-by":"crossref","unstructured":"Aristorena, M. et al. MMP-12, secreted by pro-inflammatory macrophages, targets endoglin in human macrophages and endothelial cells. Int. J. Mol. Sci. 20, 3107 (2019).","DOI":"10.3390\/ijms20123107"},{"key":"51523_CR8","doi-asserted-by":"crossref","unstructured":"Hawinkels, L. J. et al. ten Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res 70, 4141\u20134150 (2010).","DOI":"10.1158\/0008-5472.CAN-09-4466"},{"key":"51523_CR9","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1161\/CIRCULATIONAHA.112.101261","volume":"126","author":"AC Valbuena-Diez","year":"2012","unstructured":"Valbuena-Diez, A. C. et al. Oxysterol-induced soluble endoglin release and its involvement in hypertension. Circulation 126, 2612\u20132624 (2012).","journal-title":"Circulation"},{"key":"51523_CR10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1161\/HYPERTENSIONAHA.119.13348","volume":"74","author":"A Leanos-Miranda","year":"2019","unstructured":"Leanos-Miranda, A. et al. Soluble Endoglin As a Marker for Preeclampsia, Its Severity, and the Occurrence of Adverse Outcomes. Hypertension 74, 991\u2013997 (2019).","journal-title":"Hypertension"},{"key":"51523_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/0021-9150(95)05713-7","volume":"120","author":"AD Blann","year":"1996","unstructured":"Blann, A. D., Wang, J. M., Wilson, P. B. & Kumar, S. Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis 120, 221\u2013226 (1996).","journal-title":"Atherosclerosis"},{"key":"51523_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13023-021-01749-w","volume":"16","author":"J Visek","year":"2021","unstructured":"Visek, J. et al. Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients. Orphanet J. Rare Dis. 16, 110 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"51523_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.phrs.2011.03.008","volume":"64","author":"J Rathouska","year":"2011","unstructured":"Rathouska, J. et al. Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis. Pharmacol. Res. 64, 53\u201359 (2011).","journal-title":"Pharmacol. Res."},{"key":"51523_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.4103\/2045-8932.110445","volume":"3","author":"R Malhotra","year":"2013","unstructured":"Malhotra, R. et al. Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension. Pulm Circ. 3, 369\u2013380 (2013).","journal-title":"Pulm Circ."},{"key":"51523_CR15","doi-asserted-by":"publisher","first-page":"972040","DOI":"10.3389\/fmed.2022.972040","volume":"9","author":"V Tomaskova","year":"2022","unstructured":"Tomaskova, V. et al. Prognostic value of soluble endoglin in patients with septic shock and severe COVID-19. Front. Med. (Lausanne). 9, 972040 (2022).","journal-title":"Front. Med. (Lausanne)"},{"key":"51523_CR16","doi-asserted-by":"publisher","first-page":"166990","DOI":"10.1016\/j.bbadis.2023.166990","volume":"1870","author":"S Eissazadeh","year":"2024","unstructured":"Eissazadeh, S. et al. Endoglin and soluble endoglin in liver sinusoidal endothelial dysfunction in vivo. Biochim. Biophys. Acta Mol. Basis Dis. 1870, 166990 (2024).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"51523_CR17","doi-asserted-by":"publisher","first-page":"112446","DOI":"10.1016\/j.mce.2024.112446","volume":"597","author":"M Young","year":"2025","unstructured":"Young, M., McLeod, D. S. A. & Richard, K. Nicotine increases hepatocyte transthyretin turnover: A possible mechanism for the protective effect of smoking on preeclampsia? Mol. Cell. Endocrinol. 597, 112446 (2025).","journal-title":"Mol. Cell. Endocrinol."},{"key":"51523_CR18","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1096\/fj.201802245R","volume":"33","author":"M Vicen","year":"2019","unstructured":"Vicen, M. et al. Regulation and role of endoglin in cholesterol-induced endothelial and vascular dysfunction in vivo and in vitro. FASEB J. 33, 6099\u20136114 (2019).","journal-title":"FASEB J."},{"key":"51523_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.atherosclerosis.2015.10.003","volume":"243","author":"J Rathouska","year":"2015","unstructured":"Rathouska, J., Jezkova, K., Nemeckova, I. & Nachtigal, P. Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis 243, 383\u2013388 (2015).","journal-title":"Atherosclerosis"},{"key":"51523_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2018.02.008","volume":"271","author":"B Vitverova","year":"2018","unstructured":"Vitverova, B. et al. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. Atherosclerosis 271, 15\u201325 (2018).","journal-title":"Atherosclerosis"},{"key":"51523_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.lfs.2017.03.014","volume":"175","author":"M Varejckova","year":"2017","unstructured":"Varejckova, M. et al. Soluble endoglin modulates the pro-inflammatory mediators NF-kappaB and IL-6 in cultured human endothelial cells. Life Sci. 175, 52\u201360 (2017).","journal-title":"Life Sci."},{"key":"51523_CR22","doi-asserted-by":"publisher","first-page":"1116422","DOI":"10.3389\/fphar.2023.1116422","volume":"14","author":"CI Sa","year":"2023","unstructured":"Sa, C. I. et al. Labetalol and soluble endoglin aggravate bile acid retention in mice with ethinylestradiol-induced cholestasis. Front. Pharmacol. 14, 1116422 (2023).","journal-title":"Front. Pharmacol."},{"key":"51523_CR23","doi-asserted-by":"publisher","first-page":"116643","DOI":"10.1016\/j.lfs.2019.116643","volume":"232","author":"E Dolezelova","year":"2019","unstructured":"Dolezelova, E. et al. High soluble endoglin levels regulate cholesterol homeostasis and bile acids turnover in the liver of transgenic mice. Life Sci. 232, 116643 (2019).","journal-title":"Life Sci."},{"key":"51523_CR24","doi-asserted-by":"publisher","first-page":"e58955","DOI":"10.1371\/journal.pone.0058955","volume":"8","author":"T Rath","year":"2013","unstructured":"Rath, T. et al. Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease. PloS one. 8, e58955 (2013).","journal-title":"PloS one"},{"key":"51523_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/cbf.2987","volume":"32","author":"TK Motawi","year":"2014","unstructured":"Motawi, T. K., Rizk, S. M., Ibrahim, I. A. R. & El-Emady, Y. F. Alterations in circulating angiogenic and anti\u2010angiogenic factors in type 2 diabetic patients with neuropathy. Cell Biochem. Funct. 32, 155\u2013163 (2014).","journal-title":"Cell Biochem. Funct."},{"key":"51523_CR26","doi-asserted-by":"crossref","unstructured":"Igreja Sa, I. C. et al. Soluble endoglin as a potential biomarker of nonalcoholic steatohepatitis (NASH) development, participating in aggravation of NASH-related changes in mouse liver. Int J. Mol. Sci. 21, 9021 (2020).","DOI":"10.3390\/ijms21239021"},{"key":"51523_CR27","doi-asserted-by":"publisher","first-page":"544","DOI":"10.26444\/aaem\/76937","volume":"24","author":"A Prystupa","year":"2017","unstructured":"Prystupa, A. et al. Relationships between serum selenium and zinc concentrations versus profibrotic and proangiogenic cytokines (FGF-19 and endoglin) in patients with alcoholic liver cirrhosis. Ann. Agric. Environ. Med. 24, 544\u2013548 (2017).","journal-title":"Ann. Agric. Environ. Med."},{"key":"51523_CR28","doi-asserted-by":"crossref","unstructured":"de Franchis, R. et al. Corrigendum to \u2018Baveno VII - Renewing consensus in portal hypertension\u2019 [J Hepatol (2022) 959\u2013974]. J Hepatol 77, 271 (2022).","DOI":"10.1007\/978-3-031-08552-9"},{"key":"51523_CR29","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1097\/HEP.0000000000000647","volume":"79","author":"DE Kaplan","year":"2024","unstructured":"Kaplan, D. E. et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 79, 1180\u20131211 (2024).","journal-title":"Hepatology"},{"key":"51523_CR30","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.jceh.2022.03.002","volume":"12","author":"AV Kulkarni","year":"2022","unstructured":"Kulkarni, A. V., Rabiee, A. & Mohanty, A. Management of Portal Hypertension. J. Clin. Exp. Hepatol. 12, 1184\u20131199 (2022).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"51523_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/hep.28906","volume":"65","author":"G Garcia-Tsao","year":"2017","unstructured":"Garcia-Tsao, G., Abraldes, J. G., Berzigotti, A. & Bosch, J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology 65, 310\u2013335 (2017).","journal-title":"Hepatology"},{"key":"51523_CR32","doi-asserted-by":"crossref","unstructured":"Vaishnav, M. et al. and. Hepatic Venous Pressure Gradient Predicts Further Decompensation in Cirrhosis Patients with Acute Esophageal Variceal Bleeding. Diagnostics (Basel) 13 (2023).","DOI":"10.3390\/diagnostics13142385"},{"key":"51523_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3350\/cmh.2014.20.1.6","volume":"20","author":"KT Suk","year":"2014","unstructured":"Suk, K. T. Hepatic venous pressure gradient: clinical use in chronic liver disease. Clin. Mol. Hepatol. 20, 6\u201314 (2014).","journal-title":"Clin. Mol. Hepatol."},{"key":"51523_CR34","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.ajpath.2011.11.014","volume":"180","author":"TJ Kaitu\u2019u-Lino","year":"2012","unstructured":"Kaitu\u2019u-Lino, T. J. et al. MMP-14 is expressed in preeclamptic placentas and mediates release of soluble endoglin. Am. J. Pathol. 180, 888\u2013894 (2012).","journal-title":"Am. J. Pathol."},{"key":"51523_CR35","doi-asserted-by":"publisher","first-page":"123428","DOI":"10.1016\/j.lfs.2025.123428","volume":"364","author":"S Eissazadeh","year":"2025","unstructured":"Eissazadeh, S. et al. Anti-Endoglin monoclonal antibody prevents the progression of liver sinusoidal endothelial inflammation and fibrosis in MASH. Life Sci. 364, 123428 (2025).","journal-title":"Life Sci."},{"key":"51523_CR36","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.7150\/ijms.115222","volume":"22","author":"JU Rathouska","year":"2025","unstructured":"Rathouska, J. U. et al. Soluble endoglin reflects endothelial dysfunction in myocardial infarction patients: a retrospective observational study. Int. J. Med. Sci. 22, 3220\u20133228 (2025).","journal-title":"Int. J. Med. Sci."},{"key":"51523_CR37","unstructured":"Lala, V., Zubair, M. & Minter, D. A. Liver Function Tests. In StatPearls, Treasure Island (FL) (2025)."},{"key":"51523_CR38","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.2147\/IJGM.S301900","volume":"14","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z., Ma, L., Geng, H. & Bian, Y. Effects of Smoking, and Drinking on Serum Gamma-Glutamyl Transferase Levels Using Physical Examination Data: A Cross-Sectional Study in Northwest China. Int. J. Gen. Med. 14, 1301\u20131309 (2021).","journal-title":"Int. J. Gen. Med."},{"key":"51523_CR39","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1161\/ATVBAHA.125.322136","volume":"45","author":"S Yuan","year":"2025","unstructured":"Yuan, S., Damrauer, S. M. & Larsson, S. C. Alcohol, Liver Disease, and Peripheral Arterial Disease: Epidemiology, Mechanisms, and Clinical Implications. Arterioscler. Thromb. Vasc Biol. 45, 1493\u20131504 (2025).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"51523_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/alcalc\/agq028","volume":"45","author":"N Toda","year":"2010","unstructured":"Toda, N. & Ayajiki, K. Vascular actions of nitric oxide as affected by exposure to alcohol. Alcohol Alcohol. 45, 347\u2013355 (2010).","journal-title":"Alcohol Alcohol"},{"key":"51523_CR41","doi-asserted-by":"publisher","first-page":"e22315","DOI":"10.1002\/jbt.22315","volume":"33","author":"R Mohan","year":"2019","unstructured":"Mohan, R., Jose, S., Sukumaran, S., John, S. A. S. S., I, M. K. & G., and Curcumin-galactomannosides mitigate alcohol-induced liver damage by inhibiting oxidative stress, hepatic inflammation, and enhance bioavailability on TLR4\/MMP events compared to curcumin. J. Biochem. Mol. Toxicol. 33, e22315 (2019).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"51523_CR42","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/15257770802146403","volume":"27","author":"Z Peng","year":"2008","unstructured":"Peng, Z. et al. Ecto-5\u2019-nucleotidase (CD73)-mediated extracellular adenosine production plays a critical role in hepatic fibrosis. Nucleosides Nucleotides Nucleic Acids. 27, 821\u2013824 (2008).","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"51523_CR43","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11901-023-00601-y","volume":"22","author":"MJ McConnell","year":"2023","unstructured":"McConnell, M. J. & Iwakiri, Y. Portal Hypertension in Alcohol-Associated Hepatitis. Curr. Hepatol. Rep. 22, 67\u201373 (2023).","journal-title":"Curr. Hepatol. Rep."},{"key":"51523_CR44","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.jhep.2025.07.019","volume":"83","author":"N Torp","year":"2025","unstructured":"Torp, N., Israelsen, M., Thiele, M., Rinella, M. E. & Krag, A. Phosphatidylethanol in steatotic liver disease. J. Hepatol. 83, 1189\u20131203 (2025).","journal-title":"J. Hepatol."},{"key":"51523_CR45","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1159\/000526200","volume":"28","author":"JL Kummetat","year":"2022","unstructured":"Kummetat, J. L., Leonhard, A., Manthey, J., Speerforck, S. & Schomerus, G. Understanding the Association between Alcohol Stigma and Alcohol Consumption within Europe: A Cross-Sectional Exploratory Study. Eur. Addict. Res. 28, 446\u2013454 (2022).","journal-title":"Eur. Addict. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51523-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51523-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51523-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:40:39Z","timestamp":1782952839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51523-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51523"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51523-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20299"}}